In transporter-expressing cells, OSI-420 accumulation was reduced by BCRP and P-gp, with increased accumulation after elacridar treatment. MRP4 expression did not significantly change accumulation under the tested conditions. [1]
In a U87 glioblastoma cell screen, OSI-420 at 1 μM for 24 h did not significantly change average neurite-like process length per cell versus DMSO. This negative result is specific to the morphology endpoint and tested conditions. [2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Transporter-dependent OSI-420 accumulation
Cell-based study · Saos2 cells expressing BCRP or MRP4 with empty-vector controls; LLC-PK1 cells expressing human MDR1 with parental controls [1]
OSI-420 accumulation was reduced by BCRP and P-gp expression and increased by elacridar in these transfected cells. MRP4 expression produced no significant difference. These are cellular disposition endpoints, not EGFR potency or tumor-growth effects.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 μg/mL OSI-420
- Exposure duration
- Accumulation time course to 30 min; Figure 4B combines 15 and 30 min data
- Method
- Incubation at 37 °C; LC-MS/MS of cell lysates, normalized to protein
- Co-treatment
- Elacridar 4 μM comparator; 30 min pre-incubation
- Reported limits
- OSI-420 solvent and explicit biological-versus-technical identity of n=4–6 are not stated in these locations.
Methods and source locations
Compound reported in the paper: OSI-420 (O-desmethyl erlotinib); Compound label in the paper: Directly applied OSI-420 standard
Evidence concerns the reported OSI-420 material or metabolite. Hydrochloride-form equivalence and current Adooq lot performance were not tested.
Methods: Chemicals and reagents, Cell lines, Intracellular drug accumulation; Results: Intracellular accumulation experiments; Figure 4
Cellular OSI-420 accumulation relative to controls: LC-MS/MS; Figure 4: mean ± SD, n=4–6; percentages of maximum control accumulation. No exact graph percentages extracted. — Figure 4A–B and caption; Results: Intracellular accumulation experiments
No significant neurite-like process response in U87 cells
Cell-based study · U87 human glioblastoma cells in a 47-kinase-inhibitor screen [2]
OSI-420 did not significantly change average neurite-like process length per cell relative to DMSO under the screening conditions. This endpoint does not establish lack of EGFR inhibition or lack of antiproliferative activity. Later mechanistic and animal findings for CP-673451 do not apply to OSI-420.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μM
- Exposure duration
- 24 h
- Method
- Kinase inhibitor screen in 10% FBS; phase-contrast microscopy and Fiji Simple Neurite Tracer
- Vehicle
- DMSO
- Reported limits
- DMSO percentage and OSI-420-specific exact p value/effect size are not given in the checked table/caption.
Methods and source locations
Compound reported in the paper: OSI-420 (O-desmethyl erlotinib); Compound label in the paper: OSI-420 library reagent
Evidence concerns the reported OSI-420 material or metabolite. Hydrochloride-form equivalence and current Adooq lot performance were not tested.
Results: Kinase inhibitor screening; Table 1 OSI-420 row; Figure 1; Methods: Cell culture, Kinase inhibitor treatment/screening, Light microscopy and neurite-like process length analysis, Statistical analysis
Average neurite-like process length normalized by cell number versus DMSO: Table 1; Figure 1: mean ± SD of n=3 independent experiments; two-tailed t-test. Methods describe three technical repeats and nine images per well. — Table 1 OSI-420 row; Figure 1 caption; Methods: microscopy and statistics